S

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorporation Into Practice

By Sarah Tasian 2 Videos
337 views
August 9, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
16:28
Fred Hutchinson Cancer Center

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Feat. R. Cassaday
13:51
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

ALL in Adults: Overview and Recent Advances

Feat. R. Cassaday
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell T…

Feat. R. Gale
09:42
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…

Feat. M. Al Malki
31:41
MyCancerHaven

Treating Adults With Newly Diagnosed ALL

Feat. R. Vij, A. Patel
13:26
Steven Pavletic

Chronic GvHD: Main Complications After ASCT

22:30
Rush University Medical Center

Selection and Sequencing of Chronic GVHD Therapy

Feat. S. Kosuri
20:28
Insights from 2023 ASH Annual Meeting

Clinically-Relevant Updates in ALL in Adults

Feat. R. Cassaday
28:07
Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock
20:49
Salman Fazal

Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience

19:52
SOHO Brazil 2024

How Are Targeted Therapies Redefining the Treatment Paradigm in ALL …

Feat. J. Burger
37:03
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: ALL

Feat. E. Jabbour
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
12:09
Pooja Khandelwal

Treating Fibrosis and Inflammation in GvHD

06:49
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Ad…

Feat. M. Luskin